Kelsey Cole
Family Medicine · Fort Smith, ARNPI 1013778612
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,020 of the $2,393 with a category attached, or 84.4%. It is spread thinly across 32 manufacturers, the largest accounting for just 17.4% — the pattern of someone who eats at a lot of different presentations.
Across 114 payments — averaging $20.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$418
- Daiichi Sankyo Inc.$280
- Pfizer$159
- Johnson & Johnson$137
- Novartis$125
- Merck$121
- plus $1K from 26 others
What the payments were for
- Food & beverage$2,02084%
- Education$37316%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 20 | $418 |
| Daiichi Sankyo Inc. | 8 | $280 |
| Pfizer | 9 | $159 |
| Johnson & Johnson | 7 | $137 |
| Novartis | 7 | $125 |
| Merck | 7 | $121 |
| Incyte Corporation | 2 | $116 |
| Eisai Inc. | 5 | $105 |
| Seagen Inc. | 1 | $99 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $98 |
| AbbVie | 5 | $90 |
| Lilly USA, LLC | 5 | $87 |
| Pharmaessentia USA Corporation | 3 | $54 |
| Bayer | 3 | $50 |
| Regeneron Healthcare Solutions, Inc. | 3 | $49 |
| Rigel Pharmaceuticals, Inc. | 2 | $40 |
| Sanofi | 2 | $38 |
| Beigene USA, Inc. | 2 | $37 |
| Exelixis Inc. | 2 | $33 |
| E.r. Squibb & Sons, L.L.C. | 2 | $33 |
| Pharmacosmos Therapeutics Inc. | 2 | $29 |
| GSK | 2 | $28 |
| EMD Serono, Inc. | 1 | $25 |
| Beone Medicines USA, Inc. | 1 | $22 |
| Servier Pharmaceuticals LLC | 1 | $19 |
| Stemline Therapeutics Inc. | 1 | $18 |
| Karyopharm Therapeutics Inc. | 1 | $17 |
| AVEO Pharmaceuticals, Inc. | 1 | $16 |
| Geron Corporation | 1 | $15 |
| Ipsen Biopharmaceuticals, Inc | 1 | $14 |
| Jazz Pharmaceuticals Inc. | 1 | $13 |
| Iovance Biotherapeutics, Inc. | 1 | $7 |
How this compares
$2,393 in reported general payments places this provider in the 75th percentile of 1,347 family medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other family medicine in Fort Smith
- Glenn GibbonsFort Smith$179K
- Allen BeachyFort Smith$21K
- Michael CallawayFort Smith$15K
- Luc BalisFort Smith$10K
- Hetal PatelParagould$147K
- David GersonSherwood$119K
- Scott MusickBentonville$102K
- Broderick EatonWynne$49K
- Craig LevoyBentonville$30K
- Hunter CarringtonHot Springs$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.